Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension

Completed · Phase 2

Conditions studied: Orthostatic Hypotension

In brief

OBJECTIVES: I. Study further the safety and efficacy of the alpha-receptor agonist midodrine in patients with neurogenic orthostatic hypotension. II. Assess the quality of life in these patients with this treatment regimen.

Key facts

Study ID

NCT00004268

Run by

National Center for Research Resources (NCRR)

People needed

300

Starts

2001-04-01

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Mount Sinai School of Medicine — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.